TargetMol

Rubitecan

Product Code:
 
TAR-T5853
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T5853-1mL1 mL * 10 mM (in DMSO)£127.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5853-10mg10mg£135.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5853-50mg50mg£223.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5853-100mg100mg£328.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Rubitecan is a DNA topoisomerase I inhibitor. It inhibits DNA topoisomerase I and increases the fraction of supercoiled DNA in a cell-free assay in a concentration-dependent manner.Rubitecan is a semisynthetic agent related to camptothecin with potent antitumor and antiviral properties.
CAS:
91421-42-0
Formula:
C20H15N3O6
Molecular Weight:
393.35
Pathway:
DNA Damage/DNA Repair
Purity:
0.98
SMILES:
CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O
Target:
Topoisomerase

References

Sands H , Mishra A , Stoeckler J D , et al. Preclinical activity of an i.v. formulation of rubitecan in IDD-P? against human solid tumor xenografts[J]. Anti-Cancer Drugs, 2002, 13(9):965-975. Giovanella B C , Stehlin J S , Hinz H R , et al. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan)[J]. International Journal of Oncology, 2002, 20(1):81-88.